The first compound that Epistem will assess is Exponential Biotherapies’s (EBI’s) lead candidate drug, EA-230, which is a small peptide immunoregulator that has shown the potential to treat (minimize) radiation insult and could therefore be administered following a terrorist nuclear attack to reduce the level of intestinal related radiation sickness.
Zsolt Harsanyi, chairman and CEO of Exponential Biotherapies, said: “Epistem’s well established assays and unrivalled expertise in the field of gastrointestinal epithelial radiation toxicity are extremely valuable to us in confirming the potential of EA-230 as a therapeutic treatment for radionuclear attack.”